O. Nuñez

发表

Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine.

N. Young, P. Scheinberg, Colin O. Wu, 2007, The Journal of pediatrics.

Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia.

N. Young, J. Maciejewski, A. Risitano, 2002, Blood.

Gene expression profiling in CD34 cells to identify differences between aplastic anemia patients and healthy volunteers.

S. Kajigaya, N. Young, E. Billings, 2004, Blood.

Treatment of severe aplastic anaemia with combined immunosuppression: anti‐thymocyte globulin, ciclosporin and mycophenolate mofetil

N. Young, P. Scheinberg, Colin O. Wu, 2006, British journal of haematology.

Transcript profile of CD4+ and CD8+ T cells from the bone marrow of acquired aplastic anemia patients.

S. Kajigaya, N. Young, A. Risitano, 2004, Experimental hematology.

Horse versus rabbit antithymocyte globulin in acquired aplastic anemia.

N. Young, P. Scheinberg, A. Biancotto, 2011, The New England journal of medicine.

Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes

J. P. McCoy, R. Ganetzky, Xingmin Feng, 2011, Haematologica.

Late complications following treatment for severe aplastic anemia (SAA) with high-dose cyclophosphamide (Cy): follow-up of a randomized trial.

N. Young, J. Maciejewski, J. Tisdale, 2002, Blood.

Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia.

N. Young, J. Maciejewski, E. Sloand, 2003, Blood.

High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial

N. Geller, N. Young, A. Barrett, 2000, The Lancet.

Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study

N. Young, P. Scheinberg, E. Sloand, 2009, Haematologica.

Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia

N. Young, P. Scheinberg, Colin O. Wu, 2009, British journal of haematology.

Retreatment with rabbit anti‐thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia

N. Young, P. Scheinberg, O. Nuñez, 2006, British journal of haematology.

Gene expression profiling in CD 34 cells to identify differences between aplastic anemia patients and healthy volunteers

S. Kajigaya, N. Young, E. Billings, 2003 .

A Randomized Trial of Horse Versus Rabbit Antithymocyte Globulin In Severe Acquired Aplastic Anemia

N. Young, P. Scheinberg, E. Sloand, 2010 .

Long Term Outcome of Pediatric Patients with Severe Aplastic Anemia Treated with Anti-Thymocyte Globulin and Cyclosporine.

N. Young, P. Scheinberg, Colin O. Wu, 2007 .

Oral manifestations in patients with aplastic anemia.

S. Pillemer, N. Young, M. Brennan, 2001, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades.

N. Young, P. Scheinberg, T. Walsh, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Th17 immune responses contribute to the pathophysiology of aplastic anemia.

M. Desierto, K. Keyvanfar, N. Young, 2010, Blood.

Alemtuzumab (Campath) Monotherapy for Severe Aplastic Anemia.

N. Young, P. Scheinberg, E. Sloand, 2010 .

Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome.

D. Follmann, N. Young, O. Nuñez, 2003, JAMA.

Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome.

S. Chanock, P. Lansdorp, N. Young, 2003, Blood.

Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine

N. Young, P. Scheinberg, M. Marte, 2010, Haematologica.

Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia.

S. Fischer, N. Young, P. Scheinberg, 2006, Blood.

Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia.

N. Young, P. Scheinberg, Colin O. Wu, 2012, Blood.

Validation of the RIM Score-COVID in the Spanish SEMI-COVID-19 Registry

Miguel Ángel Martínez, Yale Tung Chen, Manuel Cebrian, 2023, Internal and Emergency Medicine.

Circulating Cytokine Profiles of Patients with Acquired Aplastic Anemia and Myelodysplastic Syndrome

J. P. McCoy, R. Ganetzky, Xingmin Feng, 2008 .

Cyclosporine Taper Does Not Prevent Relapse in Severe Aplastic Anemia

N. Young, P. Scheinberg, Colin O. Wu, 2011 .

Treatment of Severe Aplastic Anemia with Combined Immunosuppression: Antithymocyte Globulin (ATG), Cyclosporine A (CSA), and Mycophenolate Mofetil (MMF).

N. Young, P. Scheinberg, Colin O. Wu, 2005 .

Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes

R. Ganetzky, Xingmin Feng, N. Young, 2010, Haematologica.

Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia.

N. Young, P. Scheinberg, Colin O. Wu, 2012, Blood.